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Abstract 
Background: This study aims to assess serum vaspin in early stages of glucose intolerance and in the presence of 
metabolic syndrome (MetS); and to evaluate vaspin correlation to different cardio-metabolic parameters and auto-
nomic tone in these subjects.
Methods: 185 subjects (80 males and 105 females) of mean age 45.8 ± 11.6 years and mean BMI 31.2 ± 6.3 kg/m2, 
divided into groups according to: glucose tolerance, presence of MetS and cardio-vascular autonomic dysfunction 
(CAD), were enrolled. Glucose tolerance was studied during OGTT. Anthropometric indices, blood pressure, HbA1c, 
serum lipids, hsCRP, fasting immunoreactive insulin and serum vaspin were measured. Body composition was esti-
mated by impedance analysis. AGEs were assessed by skin fluorescence. CAD was assessed by ANX-3.0.
Results: There was no difference in vaspin levels between the groups according to glucose tolerance, presence of 
MetS, and CAD. Regression analysis revealed independent association between serum vaspin and total body fat in 
newly diagnosed type 2 diabetes (NDT2D) group, and between serum vaspin and age and total body fat in MetS 
group. Vaspin negatively correlated with both sympathetic and parasympathetic activity in normal glucose tolerance 
(NGT) and just with parasympathetic tone in NGT without MetS.
Conclusion: Our results demonstrate no overt fluctuations in vaspin levels in the early stages of glucose intolerance 
and in MetS. Total body fat seems to be related to vaspin levels in MetS and NDT2D. Our data show negative correla-
tion between vaspin and autonomic function in NGT, as vaspin is associated with parasympathetic activity even in the 
absence of MetS.
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Background
Vaspin is a visceral adipose tissue (VAT)-derived ser-
ine protease inhibitor with insulin-sensitizing effects. It 
is found in the VAT of Otsuka Long-Evans Tokushima 
Fatty rat, an animal model with central obesity and type 
2 diabetes (T2D) [1]. Uncontrolled diabetes and weight 
reduction diminish vaspin expression, whereas the 
administration of insulin sensitizers, such as pioglita-
zone, normalizes its expression and serum concentration. 
In experimental conditions recombinant vaspin adminis-
tration significantly improves glucose tolerance and insu-
lin sensitivity [1, 2]. There is some evidence that vaspin 
has the potential to increase adipocyte insulin sensitiv-
ity and to suppress obesity through promoting the dif-
ferentiation of 3T3-L1 preadipocytes by decreasing IL-6 
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on these data it has been assumed that vaspin serves as 
an insulin sensitizer with anti-inflammatory effects [1, 2].
A meta-analysis, encompassing six studies including 
1826 obese individuals and 11 studies including 1570 
subjects with T2D has been conducted. It provides evi-
dence of higher vaspin levels in obesity and T2D and 
emphasizes the pivotal role of vaspin in the progression 
of metabolic and glucose abnormalities [4].
The results of a growing number of studies in differ-
ent ethnic groups have shown that cardiovascular auto-
nomic dysfunction (CAD) is present in the early stages 
of abnormal glucose homeostasis [5, 6] and suggested 
its multifactorial modality and its relation to a num-
ber of cardio-metabolic risk factors. Central obesity is 
a confirmed risk marker for CAD [7], probably due to 
increased adipokine synthesis and secretion from VAT.
The impact of vaspin in the early stages of glucose 
intolerance is still poorly studied and the role of vaspin 
for the development of metabolic syndrome (MetS), dia-
betes and its chronic complications is not totally clarified. 
The present study aims to assess serum vaspin levels in 
the early stages of glucose tolerance impairments, in the 
presence of MetS, and CAD, and to evaluate the associa-
tion between serum vaspin and different cardio-meta-
bolic parameters and cardiovascular autonomic function 
(CAF) in these subjects.
Methods
A total of 185 subjects—80 males and 105 females, 
mean age 45.8 ± 11.6 (from 18 to 82 years), mean BMI 
31.2  ±  6.3  kg/m2 were included in this cross-sectional 
study. They were divided into groups according to their 
glucose tolerance category, presence of MetS, and CAD. 
The main characteristics of the groups are displayed in 
Fig. 1.
Participants were recruited at the Department of Dia-
betology, Clinical Centre of Endocrinology, Medical Uni-
versity, Sofia within a screening program for diabetes 
mellitus.
All subjects declared their written informed consent 
and were familiar with the aims, methods and risks of 
participating in the study in accordance with the Hel-
sinki Declaration and rules of Good Clinical Practice, as 
the study was approved by the Ethics Committee of the 
Medical University, Sofia.
All participants were interviewed for previously diag-
nosed diabetes and anti-diabetic therapy, arrhythmias 
and anti-arrhythmic drug administration, the presence of 
ischemic heart disease and experienced vascular events, 
which were adopted as exclusion criteria.
Anthropometric parameters were measured—height, 
weight and waist circumference (measured in a horizon-
tal plane, the midline between the inferior margin of the 
12th rib and the superior border of the iliac crest), and 
BMI was calculated.
Categories of glucose tolerance were evaluated during a 
standard oral glucose tolerance test with 75 g anhydrous 
glucose after an overnight fast. Fasting and a 120-min 
plasma glucose were examined by a hexokinase enzyme 
method (Roche Diagnostics). The glucose tolerance was 
defined according to 2006 WHO criteria. Fasting immu-
noreactive insulin (IRI) was measured using electrochem-
iluminescence immunoassay (ECLIA Roche Diagnostics) 
and homeostasis model assessment of insulin resistance 
and beta-cell function (HOMA-IR and HOMA-β) was 
defined according to Matthews et al. formulas [8].
Serum lipid parameters (total cholesterol, HDL choles-
terol and triglycerides using an enzymatic colorimetric 
method (Roche Diagnostics), LDL cholesterol was cal-
culated using Fridewald’s formula), HbA1c (NGSP certi-
fied) in whole blood samples using immunoturbidimetric 
method (Roche Diagnostics), high sensitive C-reactive 
protein (hsCRP) using a particle-enhanced turbidimet-
ric method (CRP-Latex) (Roche Diagnostics), with an 
intra-assay coefficient of variation of less than 3.6 % and 
inter-assay coefficient of variation of less than 11.1  %, 
measuring range 0–160  mg/l (0–1600  mg/l with postdi-
lution) and limit of quantification 0.085 mg/l, and serum 
vaspin using ELISA method (BioVendor), with an intra-
assay coefficient of variation of less than 7.6 % and inter-
assay coefficient of variation of less than 7.7 %, and limit 
of quantification 0.01 ng/ml, according to manufacturer᾽s 
protocol, were assessed in all participants at fasting.
Arterial blood pressure was measured in standard con-
ditions. Body composition was estimated by impedance 
analysis (InBody 720). Visceral fat area was calculated in 
cm2 and total body fat was presented in  %.
The 2005 IDF definition of the MetS was used.
Tissue advanced glycation end products (AGEs) accu-
mulation was assessed non-invasively measuring the skin 
autofluorescence of ultraviolet light on the ventral side of 
the lower arm (AGE-Reader-DiagnOpticsTM).
ANS function evaluation was performed with ANS-3.0 
autonomic monitoring system (ANSAR Medical Tech-
nologies, Inc., Philadelphia, PA)—software that computes 
sympathetic and parasympathetic nervous system activ-
ity using “frequency-domain” analysis at rest and apply-
ing standard clinical tests: 1. deep breathing; 2. valsalva 
maneuver; and 3. standing from a seated position. The 
ANS-3.0 method, focused on the low-frequency range of 
the spectrum fixed between 0.04 and 0.15 Hz, computes 
sympathetic (low frequency area—LFa) and parasympa-
thetic (respiratory frequency area—RFa) activity simul-
taneously and independently, applying spectral analysis 
of respiratory activity with concomitant spectral analy-
sis of heart rate variability (HRV). The parasympathetic 
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portion is defined as centered on the fundamental res-
piratory frequency-RFa and the remaining portion of the 
analysis interval of HRV spectrum corresponds to the 
sympathetic activity—LFa, measured in bpm2.
As 49 subjects presented with arterial hypertension 
(blood pressure >140/90 mmHg) on treatment with dif-
ferent classes of antihypertensive drugs, including beta- 
and alpha-blockers, the study was performed at least 24 h 
after the last dose of medications affecting autonomic 
function—antihypertensives, tricyclic antidepressants 
and SSRIs, refraining from coffee and smoking 12 h prior 
to the test, at least 30 min after the last meal, between 8 
and 11am in the morning.
Statistical analysis
Statistical analysis of the data was performed by SPSS 
21.0 (SPSS, Chicago, USA). The data is expressed as 
mean ± standard deviation (SD) and median (percentile 
25–75  %). Mann–Whitney U and Kruskal–Wallis one-
way analysis of variance (One-way ANOVA) were used 
to compare independent non-normally distributed vari-
ables. Logarithmic transformation was used for skewed 
data distribution. Associations between normally dis-
tributed different measured parameters or their log scale 
were analyzed using Pearson correlation and stepwise 
multiple linear regression models. A p value (two tailed) 
of less than 0.05 was considered statistically significant.
Results
No significant difference in serum vaspin levels between 
the groups according to glucose tolerance, presence of 
MetS, and CAD, as well as between the subgroups with 
normal glucose tolerance (NGT) with and without MetS 
was observed (Fig. 2). There were no gender differences 
in circulating vaspin levels (p = 0.078).
Serum vaspin correlated positively with total body 
fat and negatively with fasting plasma glucose and 
HbA1c in the newly-diagnosed type 2 diabetes group 
(NDT2D). The NGT +  MetS group showed a positive 
correlation between serum vaspin and age, and AGEs, 
whilst in NGT–MetS group serum vaspin significantly 
correlated with age. The groups with MetS demon-
strated a positive correlation between vaspin and age, 
total body fat, and AGEs, whereas in those without 
total (n=185)
1) 80/105 
2) 45.8±11.6  
3) 31.2±6.3  



















































Fig. 1 Main characteristics [number, gender distribution, mean age and body mass index (BMI)] of the participants in the groups according to glu-
cose tolerance category—NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, and newly-diagnosed type 
2 diabetes (NDT2D), with (MetS+) and without (MetS−) Metabolic syndrome, and with (CAD+) and without (CAD−) cardio-vascular autonomic 
dysfunction n—number, (1) gender (males/females), (2) age (years), (3) BMI (kg/m²), (4) serum vaspin concentration (ng/ml). Data is means ± SD 
and median (percentile 25–75 %)
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MetS there was a correlation just between vaspin and 
age (Table 1).
Serum vaspin concentrations presented a negative 
correlation with both sympathetic and parasympathetic 
activity at rest, during deep breathing, Valsalva, and 
standing in NGT group. The subjects in NGT +  MetS 
subgroup showed a strong negative correlation between 
serum vaspin and sympathetic tone at rest, both sym-
pathetic and parasympathetic tone during deep breath-
ing, and standing, whilst in NGT-MetS subgroup vaspin 
negatively correlated just with parasympathetic power 
at rest and during applied clinical tests (Table  2). No 
significant correlation between serum vaspin and auto-
nomic tone in the groups with glucose intolerance was 
observed.
A stepwise multiple regression analysis was conducted 
to assess the predictive value of these variables for serum 
vaspin levels. Age and total body fat entered into the regres-
sion and were related to vaspin in the presence of MetS 
(F [2, 113] = 7.86 (2, 113), p = 0.001), total body fat was 
related to vaspin in NDT2D (F [1, 33] = 6.01, p < 0.020), 
parasympathetic tone during deep breathing was related to 
vaspin in NGT–MetS (F [1, 33] = 8.92, p < 0.005), and sym-
pathetic tone at rest was related to vaspin in NGT + MetS 
(F [1, 33]  =  5.36, p  <  0.027). The multiple correlation 
coefficients were 0.107, 0.403, 0.461 and 0.374, respectively, 
showing that 12.2 % of the variance of vaspin levels might 
be accounted for by age and total body fat in MetS, 16.2 % 
by total body fat in NDT2D, 21.3  % by parasympathetic 
activity during in NGT – MetS, and 14.0 % by sympathetic 
activity at rest in NGT + MetS (Table 3).
Discussion
Our results demonstrated no significant difference in 
vaspin levels between the groups according to glucose 
tolerance and the presence of MetS. No correlation 
between serum vaspin and IRI levels, HOMA-IR and 
HOMA-β was established in the same groups as well. 
In accordance with our results some recent studies have 
presented no difference in vaspin levels between sub-
jects with T2D and MetS as compared to those without 
MetS [9], or even lower vaspin concentrations in men 
with MetS [10] and a reciprocal relation between serum 
vaspin and insulin levels [11]. Other studies have found 
no difference in vaspin levels between NGT women with 
and without obesity [12] and reported no relationship 
between vaspin concentrations and insulin sensitivity in 
men [13] and in both genders [14] as well.
Despite some observations for an independent relation 
between serum vaspin and VAT in the presence of high 
Fig. 2 Serum vaspin levels in the groups according to glucose tolerance NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired 
glucose tolerance, NDT2D newly-diagnosed type 2 diabetes, the presence of metabolic syndrome (without MetS and with MetS), the presence 
of cardio-vascular autonomic dysfunction (without CAD and with CAD), and in the NGT subgroups according to the presence of MetS (without 
NGT – MetS and with NGT + MetS)
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Table 1 Correlation between serum vaspin levels and age, glycemia, body fat distribution, indices for  insulin secretion 
and insulin resistance (HOMA-β, HOMA-IR) and hsCRP in the groups according to glucose tolerance [normal glucose tol-
erance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and  newly-diagnosed type 2 diabetes 
(NDT2D)] and the presence of Metabolic syndrome (MetS)
Vaspin Vaspin
Corr coeff (r) P Corr coeff (r) P
NGT IFG
 Age 0.35 0.003  Age 0.16 0.373
 Fasting plasma glucose 0.1 0.394  Fasting plasma gucose 0.01 0.992
 HbA1c 0.17 0.157  HbA1c −0.17 0.325
 AGEs 0.18 0.144  AGEs −0.12 0.486
 BMI −0.01 0.987  BMI 0.14 0.431
 Total body fat 0.23 0.055  Total body fat −0.05 0.762
 Visceral fat area 0.12 0.318  Visceral fat area 0.22 0.212
 Fasting serum insulin −0.16 0.178  Fasting serum insulin 0.15 0.407
 HOMA-β −0.18 0.143  HOMA-β 0.12 0.483
 HOMA-IR −0.14 0.237  HOMA-IR 0.16 0.371
 hsCRP 0.08 0.518  hsCRP −0.23 0.188
NGT + MetS IGT 
 Age 0.31 0.042  Age 0.23 0.201
 Fasting plasma glucose 0.05 0.768  Fasting plasma glucose 0.13 0.451
 HbA1c 0.25 0.140  HbA1c 0.18 0.313
 AGEs 0.45 0.006  AGEs 0.07 0.710
 BMI 0.11 0.533  BMI −0.28 0.107
 Total body fat 0.28 0.110  Total body fat −0.3 0.088
 Visceral fat area 0.1 0.560  Visceral fat area −0.25 0.156
 Fasting serum insulin −0.25 0.148  Fasting serum insulin −0.1 0.451
 HOMA-β −0.25 0.148  HOMA-β −0.19 0.286
 HOMA-IR −0.24 0.165  HOMA-IR −0.05 0.779
 hsCRP 0.14 0.438  hsCRP −0.17 0.325
NGT – MetS NDT2D
 Age 0.41 0.015  Age 0.05 0.791
 Fasting plasma glucose 0.24 0.168  Fasting plasma glucose −0.4 0.023
 HbA1c 0.11 0.529  HbA1c −0.37 0.036
 AGEs −0.05 0.799  AGEs −0.11 0.539
 BMI −0.05 0.771  BMI 0.26 0.138
 Total body fat 0.21 0.222  Total body fat 0.43 0.013
 Visceral fat area 0.28 0.102  Visceral body fat 0.06 0.740
 Fasting serum insulin −0.01 0.939  Fasting serum insulin 0.12 0.504
 HOMA-β −0.09 0.618  HOMA-β 0.29 0.101
 HOMA-IR 0.02 0.918  HOMA-IR −0.06 0.736
 hsCRP 0.11 0.543  hsCRP −0.04 0.835
MetS+ MetS−
 Age 0.22 0.019  Age 0.36 0.006
 Fasting plasma glucose 0.16 0.079  Fasting plasma glucose 0.18 0.185
 HbA1c 0.15 0.110  HbA1c 0.09 0.531
 AGEs 0.2 0.036  AGEs −0.16 0.242
 BMI 0.17 0.074  BMI −0.13 0.348
 Total body fat 0.2 0.032  Total body fat 0.04 0.797
 Visceral fat area 0.16 0.094  Visceral fat area 0.01 0.958
 Fasting serum insulin 0.06 0.525  Fasting serum insulin −0.14 0.325
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HOMA-IR [15], our results revealed a significant correla-
tion between serum vaspin and total body fat in NDT2D 
and in the presence of MetS in accordance with Kloting 
et al. study. This controversy is probably due to the fact that 
vaspin mRNA expression have been described just in 23 % 
of VAT and 15  % of subcutaneous adipose tissue (SAT) 
samples and no correlation between visceral vaspin gene 
expression and VAT and SAT areas have been observed 
[16]. Furthermore, another study has reported vaspin 
mRNA expression predominantly in nonfat cells [17].
A number of previously reported data have shown a 
correlation between vaspin levels and insulin sensitiv-
ity and obesity indices [15, 18–22]. Flehming et al. have 
conducted cluster analysis of 20 adipokines, including 
vaspin, to compare their predictive value for the pres-
ence of T2D with a set of traditional markers—HbA1c, 
HOMA-IR and fasting plasma glucose. Contrary to the 
expectations this cluster has shown lower sensitivity 
and specificity [23]. Hence, although it is assumed that 
vaspin has putative insulin-sensitizing properties, prob-
ably the relationship between vaspin and the parameters 
of insulin sensitivity might be significantly altered by 
the presence of glucose tolerance impairments in obese 
individuals.
We found a positive correlation between serum vaspin 
and AGEs accumulation in subjects with MetS indepen-
dently of their glucose tolerance. It has been implied that 
vaspin protects endothelial cells via inhibition of NF-kB 
[24]. On the other hand, endothelial injury is mediated by 
AGEs via up-regulation of the same transcription factor 
[25]. In this line it could be assumed that vaspin serves as 
a compensatory mechanism against to oxidative stress in 
MetS.
It has been suggested that vaspin exerts anti-inflam-
matory effects [22] and hsCRP independently predicts 
circulating vaspin level in chronic dialysis patients [26]. 
Contrary to the above, we did not identify any correla-
tion between vaspin and hsCRP in the studied groups. A 
limitation of our analyses is that inflammation has been 
only characterized by circulating hsCRP and inclusion 
of additional markers of inflammation may change this 
result.
Kempf et  al. have identified a correlation between 
vaspin gene single nucleotide polymorphism rs2236242 
and T2D with genotype AA. It has been assumed that 
vaspin might be a new link between obesity and related 
glucose metabolism disorders [27]. Our findings revealed 
a negative correlation between serum vaspin and fast-
ing plasma glucose and HbA1c levels in NDT2D group, 
whereas there was no correlation between vaspin and 
Table 1 continued
Vaspin Vaspin
Corr coeff (r) P Corr coeff (r) P
 HOMA-β −0.01 0.886  HOMA-β −0.21 0.130
 HOMA-IR 0.09 0.347  HOMA-IR −0.08 0.553
 hsCRP 0.01 0.916  hsCRP −0.07 0.625
Statistical significant values are presented in italics
Table 2 Correlation between serum vaspin levels and sym-
pathetic (LFa) and  parasympathetic (RFa) activity at  rest 
and during clinical tests in the NGT group and in the sub-
groups with (NGT + MetS) and without (NGT – MetS) Meta-
bolic syndrome
Statistical significant values are presented in italics
NGT Vaspin
Corr coeff (r) P
 LFa at rest −0.31 0.010
 RFa at rest −0.3 0.010
 LFa deep breathing −0.24 0.042
 RFa deep breathing −0.42 <0.001
 LFa valsalva maneuver −0.24 0.043
 RFa valsalva maneuver −0.33 0.006
 LFa standing −0.31 0.009
 RFa standing −0.34 0.004
NGT + MetS
 LFa at rest −0.39 0.021
 RFa at rest −0.31 0.066
 LFa deep breathing −0.41 0.016
 RFa deep breathing −0.35 0.038
 LFa Valsalva maneuver −0.18 0.311
 RFa Valsalva maneuver −0.24 0.158
 LFa standing −0.36 0.035
 RFa standing −0.34 0.049
NGT – MetS
 LFa at rest −0.2 0.251
 RFa at rest −0.38 0.025
 LFa deep breathing −0.05 0.774
 RFa deep breathing −0.51 0.002
 LFa valsalva maneuver −0.29 0.096
 RFa valsalva maneuver −0.42 0.013
 LFa standing −0.27 0.118
 RFa standing −0.38 0.023
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glycemic parameters in prediabetes and NGT groups. 
Although we observed a trend towards higher serum 
vaspin levels in the groups with the worsening of glucose 
intolerance, the difference was not statistically signifi-
cant. Li et  al. have reported similar results, establish-
ing elevated serum vaspin only in NDT2D [28]. Other 
authors have observed elevated vaspin levels in obese 
subjects with NGT [29] and in prediabetes [30]. Data on 
serum vaspin levels in T2D are rather conflicting. Some 
studies have demonstrated increased vaspin concen-
trations [28, 31], others have reported no difference in 
vaspin levels [18], or even decreased vaspin concentra-
tions [32, 33] in T2D. Taking into account diabetes dura-
tion Atya et al. and Feng et al. have found a reduction in 
circulating vaspin in subjects with longer diabetes dura-
tion [29, 34]. Based on these ambivalent data it could be 
speculated that, if vaspin plays a compensatory role in 
glucose metabolism disorders, it manifests at relatively 
early stages of glucose intolerance, namely at the onset 
of T2D, and its secretion capacity gradually declines with 
the increase of diabetes duration.
There are limited data on vaspin relation to diabetes 
chronic complications. Gulcelik et  al. have demonstrated 
diminished vaspin levels in the presence of microvascular 
complications [32] and Li et al. in the presence of macroan-
giopathy [35]. It has been suggested that vaspin regulates 
eNOS function in endothelial progenitor cells in subjects 
with diabetes and thus prevents the occurrence of vascu-
lar complications [36]. If there is any impact on peripheral 
nerve fibers is still unclear. As far as we know the relation 
between vaspin levels and CAF has been investigated only 
in adolescent subjects with type 1 diabetes and there are 
no data in adults. El Dayem et al. study has shown a sig-
nificant relation between serum vaspin and a standard 
deviation difference RR as a time domain HRV parameter 
of CAF, assessed by 24-h holter monitoring [37]. Our find-
ings displayed a significant negative correlation between 
vaspin and both sympathetic and parasympathetic activity 
at rest and during clinical tests just in NGT group. After 
subdividing this group according to the presence of MetS 
serum vaspin was independently related to sympathetic 
activity in NGT  +  MetS group and to parasympathetic 
activity in NGT – MetS group. As there was no associa-
tion between vaspin concentrations and autonomic activ-
ity in the groups with glucose intolerance, it has probably 
been obscured by dysglycemia. Vinik’s classification of 
CAD stages based on the high-sensitive ANX-3.0 method, 
applied in the present study, defines early parasympathetic 
weakness [38], which is observed even in the absence of 
insulin resistance [39]. This assumption clarifies the nega-
tive correlation of vaspin with parasympathetic tone in 
NGT – MetS group and with sympathetic tone only in the 
presence of MetS. Insulin resistance, endothelial dysfunc-
tion and overproduction of adipokines are likely accompa-
nying mechanisms for the development of CAD [40, 41]. 
Based on our finding and Chang et al. data [39] it might 
be speculated that probably insulin resistance is a conse-
quence of existing autonomic damage and vaspin exerts 
its protective effects long before the development of meta-
bolic syndrome abnormalities.
Table 3 Main determinants of  serum vaspin in  the groups with  metabolic syndrome (MetS +), newly-diagnosed type 
2 diabetes (NDT2D), normal glucose tolerance (NGT), and in the NGT subgroups with (NGT + MetS) and without (NGT–
MetS) MetS
ln—natural logarithmic transformation for skewed data distribution
Statistical significant values are presented in italics
Stepwise multiple regression (t, p) F (df) p R R2
Predictor variable
Invaspin (MetS+)
 Model 1: age (3.20, p = 0.002) 10.22 (1.114) p = 0.002 0.074 0.082
 Model 2: age total body fat (3.10, p = 0.002)
(2.26, p = 0.026)
7.86 (2.113) p = 0.001 0.107 0.122
lnvaspin (NDT2D)
 Model 1: total body fat (2.45, p < 0.020) 6.01 (1.33) p = 0.020 0.403 0.162
lnvaspin (NGT)
 Model 1: ln(RFa deep breathing) (−3.16, p = 0.002) 10.0 (1.68) p = 0.002 0.358 0.128
lnvaspin (NGT – MetS)
 Model 1: ln(RFa deep breathing) (−2.99, p = 0.005) 8.92 (1.33) p = 0.005 0.461 0.213
lnvaspin (NGT + MetS)
 Model 1: ln(LFa at rest) (−2.31, p = 0.027) 5.36 (1.33) p = 0.027 0.374 0.140
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Conclusion
Our results demonstrate no overt fluctuations in vaspin 
levels in the early stages of glucose intolerance and in 
MetS. Total body fat and age seem to influence vaspin in 
MetS, and just total body fat in NDT2D. Our data show 
negative correlation between vaspin and CAF in normo-
glycemia, as vaspin is associated with parasympathetic 
activity even in the absence of MetS.
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